Background {#Sec1}
==========

The B-Raf proto-oncogene serine/threonine kinase (B-Raf) is a strong activator of the extracellular signal-regulated kinase/mitogen-activated protein kinase 1 and 2 (Erk 1/2) signal transduction cascade that mediates cell proliferation \[[@CR1]\]. Most *BRAF* mutations occur at codon 600, which resides within the activation loop of the kinase domain, and 80% to 90% of these mutations generate a protein with a glutamic acid (E) residue substituted for the normal valine (V) residue (*BRAF* V600E). Such mutant proteins exhibit increased kinase activity and transform cultured cells. The *BRAF* V600E mutation occurs frequently in certain brain tumors such as pleomorphic xanthoastrocytoma (PXA) (60%), PXA with anaplastic features (60%), ganglioglioma (20% to 60%), extracerebellar pilocytic astrocytoma (20%) \[[@CR2]-[@CR5]\], epithelioid glioblastoma (54%) \[[@CR6]\], and giant cell glioblastoma (7%) \[[@CR5]\]. However, the few studies of adult classical glioblastoma (c-GBM) with the *BRAF* V600E mutation lack detailed characterization of the tumors. Here, we present the first report, to our knowledge, that combines histopathological, immunohistochemical, and next-generation sequencing (NGS) analyses of c-GBM with the *BRAF* V600E mutation.

Case presentation {#Sec2}
=================

A 49-year-old man was admitted to the hospital complaining of headache, vomiting, and mild left hemiparesis. Magnetic resonance imaging (MRI) showed a huge multicystic mass in the right occipitoparietal area with marked surrounding edema and a shift of the midline structures to the left side (Figure [1](#Fig1){ref-type="fig"}A). The cyst wall and adjacent cortical mass were enhanced with contrast medium (Figure [1](#Fig1){ref-type="fig"}B). 18F-Fluorodeoxyglucose (FDG) and methionine (MET) positron emission tomography (PET) revealed high accumulation in the right occipitoparietal area (Figure [1](#Fig1){ref-type="fig"}C, D).Figure 1**Magnetic resonance imaging (MRI) and positron emission tomography (PET). (A)** T2-weighted image showing a huge multicystic mass in the right occipitoparietal area with marked surrounding edema and shift of the midline structures to the left side. **(B)** Each cyst wall and adjacent cortical mass was enhanced with contrast medium. **(C)** Fluorodeoxyglucose (FDG) PET showing high accumulation in the right occipitoparietal area. **(D)** Methionine (MET) PET showing high accumulation in the right occipitoparietal area. **(E, F)** MRI and PET findings at the time of recurrence. **(E)** Small enhanced mass adjacent to the cavity formed by removal of the tumor. (F) FDG-PET showing no accumulation in the mass. **(G)** MET-PET showing high accumulation in the mass. **(H)** MRI 4 years after the first operation.

Near-total resection of the tumor was performed. After glioblastoma (GBM) was pathologically diagnosed, the patient had local radiation using tomotherapy (60 Gy/30 fractions), with concomitant chemotherapy consisting of temozolomide (75 mg/m^2^/day). After a 4-week break, the patient received 19 cycles of adjuvant temozolomide (150 mg/m^2^/day) for 5 days every 28 days. A small contrast-enhancing lesion was seen on MRI close to an extraction cavity 22 months after the first operation. Because MET-PET showed a high accumulation in the mass, although none was detected using FDG-PET (Figure [1](#Fig1){ref-type="fig"}F, G), a second operation was performed, and the recurrence of GBM was diagnosed. Furthermore, the patient continues to receive 31 cycles of adjuvant temozolomide (200 mg/m^2^/day) for 5 days every 28 days and is living without recurrence 4 years after the first operation (Figure [1](#Fig1){ref-type="fig"}H).

Pathological findings {#Sec3}
---------------------

Numerous atypical spindle cells were interspersed with gemistocytes (Figure [2](#Fig2){ref-type="fig"}A, D), and microvascular proliferation and pseudopalisading were present (Figure [2](#Fig2){ref-type="fig"}B, C). Tumor cells were highly positive for glial fibrillary acidic protein (GFAP; Figure [2](#Fig2){ref-type="fig"}E), and the Ki67 index was approximately 10% (Figure [2](#Fig2){ref-type="fig"}F). Expression of cytokeratins was undetectable in EMA^+^ tumor cells (Figure [2](#Fig2){ref-type="fig"}G, H). Findings of tumor cells negative for epidermal growth factor receptor (EGFR) but positive for P53 are typical of secondary GBM (Figure [2](#Fig2){ref-type="fig"}I, J). Expression of the *IDH1* R132H mutant or the *IDH1* R132H mutation was not detected using immunohistochemistry or NGS analysis, respectively (Figure [2](#Fig2){ref-type="fig"}K). In contrast, expression of the *BRAF* V600E mutant was detected using immunohistochemistry, and the *BRAF* V600E mutation was detected using NGS (Figure [2](#Fig2){ref-type="fig"}L).Figure 2**Histopathological features of the** ***BRAF*** **V600E-positive glioblastoma. (A-D)** Hematoxylin and eosin **(H & E)** staining. **(A, D)** Multiple atypical spindle cells mixed with gemistocytes. **(B)** Microvascular proliferation, **(C)** pseudopalisading, **(E)** GFAP positive, **(F)** Ki67 (index was approximately 10%), **(G)** EMA positive, **(H)** pan-cytokeratin (AE1/AE3) negative, **(I)** EGFR negative, **(J)** P53 positive, **(K)** IDH1 negative, and **(L)** *BRAF* V600E positive.

DNA extraction and NGS {#Sec4}
----------------------

DNA was extracted from formalin-fixed paraffin-embedded (FFPE) sections using a NucleoSpin DNA FFPE XS Kit (Macherey-Nagel, Düren, Germany), and 225 ng of each genomic DNA sample was subjected to target amplification and library preparation for NGS analysis using a HaloPlex Cancer Research Panel (ABL1, JAK2, AKT1, JAK3, ALK, KIT, AR KRAS, ATM, MAP2K1, BRAF, MAP2K4, CDKN2A, MET, CSF1R, NOTCH1, CTNNB1, NPM1, EGFR, NRAS, ERBB2, PDGFRA, ERBB4, PIK3CA, FANCA, PIK3R1, FANCC, PTEN, FANCF, RET, FANCG, RUNX1, FGFR1, SMAD4, FGFR2, SMO, FGFR3, SRC, FLT3, STK11, HRAS, TP53, IDH1, VHL, IDH2, WT1, MAP2K2; Agilent Technologies, Santa Clara, CA, USA) according to the manufacturer's instructions. The target enrichment library pool was sequenced using a MiSeq (Illumina, San Diego, CA, USA). The sequence data were aligned, analyzed, and visualized using SureCall 2.0 software (Agilent Technologies).

Immunohistochemistry {#Sec5}
--------------------

Blocks of FFPE tumor sections were cut to a thickness of 4 μm, deparaffinized, and treated with an antigen unmasking solution (Immunosaver, Nissin EM Co. Ltd., Tokyo, Japan) at 90°C for 45 min and incubated with blocking solution (3% H~2~O~2~) at room temperature. The anti-BRAF V600E (VE1) antibody (Ventana Medical Systems, Tucson, AZ, USA) was diluted 1:2,000 and incubated with sections for 16 h at 4°C. Antibody-antigen reactions were detected using Bond Polymer Refine Detection reagents (Leica Biosystems, St. Louis, MO, USA). Additional sections were incubated for 1 h at room temperature in phosphate-buffered saline (PBS) with the antibodies as follows: ready-to-use formats of anti-GFAP clone GA5, anti-Ki67 clone SP6, anti-EMA clone E29, anti-pan-cytokeratin clone AE1/AE3, and anti-EGFR clone 31G7 (all from Nichirei Bioscience, Tokyo, Japan); anti-P53 antibody diluted 1:100 (Dako, Glostrup, Denmark); or an anti-isocitrate dehydrogenase 1 (IDH1) R132H antibody clone H09 diluted 1:50 (Dianova, Hamburg, Germany). After incubation with primary antibodies, the sections were reacted with a peroxidase-conjugated secondary antibody (catalog number 424154, Nichirei Bioscience) for 1 h at room temperature and rinsed with PBS. The Histofine DAB kit (Nichirei Bioscience) was used to detect antigen-antibody complexes.

Conclusions {#Sec6}
===========

The *BRAF* V600E mutation may occur at low frequency in adult c-GBM. This mutation was detected by the direct sequence method of Sanger method or immunohistochemistry. NGS techniques are in wide use because mutations are detected with greater sensitivity compared with Sanger sequencing \[[@CR7],[@CR8]\]. Therefore, we have performed NGS analysis to detect *BRAF* mutations in tissues of 13 patients with c-GBM (11 primary and 2 secondary cases) who were treated at Hokuto Hospital. However, the *BRAF* V600E mutation was detected in only one case (7.7%; Table [1](#Tab1){ref-type="table"}). The validity of the data is supported by the detection of *BRAF* V600E in the tumor tissue of the same patient after the tumor recurred.Table 1**Result of next-generation sequencing analysis of glioblastomaCaseAgeGenderTypeGeneIDDepthCodonAmino acid**139MPrimaryFANCArs2239359264Ggc/AgcG501SSTK11rs59912467157ttC/ttGF354L249MPrimaryPDGFRA458cCg/cGgp553RBRAFrs121913227311gTg/gAgV600EFANCArs22393591,141Ggc/AgcG501SRecurrencePDGFRA458cCg/cGgp553RBRAFrs121913227311gTg/gAgV600EFANCArs22393591,141Ggc/AgcG501S360MPrimaryVHLrs3690180048,156Ctg/GtgL129VFANCArs223935914,888Ggc/AgcG501S442FSecondaryFANCArs22393599,366Ggc/AgcG501S555MSecondaryIDH1rs1219135004,571cGt/cAtR132HATM14,928Ggt/AgtG2695SFANCArs223935918,284Ggc/AgcG501S679MPrimaryFANCArs223935918,284Ggc/AgcG501S780MPrimaryFANCArs22393593,313Ggc/AgcG501SSTK11rs599124672,723ttC/ttGF354L880MPrimaryFANCArs223935918,161Ggc/AgcG501S958MPrimaryFANCArs223935918,161Ggc/AgcG501SSTK11rs599124672,723ttC/ttGF354L1062MPrimaryFANCArs2239359513Ggc/AgcG501S1166MPrimaryFANCArs22393598,387Ggc/AgcG501S1263FPrimaryPDGFRArs22282302,959gtC/gtTV824FANCArs22393597,658Ggc/AgcG501S1362MPrimaryFANCArs22393598,036Ggc/AgcG501S

When we reviewed the pathology of this case, the tumor was not an epithelioid or a giant cell GBM because foci with glandular and ribbon-like epithelial structures and multinucleated giant cells were not present. Classical GBM was confirmed by two expert neuropathologists (H.N. and S.T).

Although there is no detailed report of a *BRAF* V600E-positive adult c-GBM, to our knowledge, there is a study of two such cases \[[@CR9]\]. The tumors of both patients were located within the right parietal lobe. Interestingly, the tumor of our present patient was located in the right occipitoparietal lobe. Moreover, our patient with BRAF V600E-positive adult c-GBM was alive when this manuscript was submitted, 4 years after the first operation. In contrast, the patients studied by Chi et al. \[[@CR9]\] survived for 19 and 36 months. The *IDH1* mutation serves as a good prognostic factor for patients with GBM but was not detectable using NGS or immunohistochemical analyses. These data are consistent with the results of a study of two patients with *BRAF* V600E-positive c-GBM \[[@CR9]\].

Although the number of patients was small, these three patients with *BRAF* V600E-positive GBM survived relatively longer compared with patients without this mutation. Therefore, tumors with the *BRAF* V600E mutation may represent a more favorable subtype of GBM. More patients with GBM must be analyzed to conclude that the *BRAF* V600E mutation is a potential prognostic marker for GBM. Moreover, inhibitors of B-Raf protein kinase activity may serve as efficacious drugs for treating patients with *BRAF* V600E-positive GBM \[[@CR10],[@CR11]\]. Therefore, we suggest that we should perform routine genetic testing of *BRAF* V600E mutation, which might provide effective alternatives to treat patients with GBM.

Consent {#Sec7}
=======

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
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